ArticleOral health & preventive dentistry2025
A Risk Score Model Based on Drug-Sensitivity-Related Genes Has the Potential to Predict Oral Squamous Cell Carcinoma Prognosis.
Article in Oral health & preventive dentistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a risk score model based on drug-sensitivity-related genes to predict the prognosis of patients with oral squamous cell carcinoma (OSCC). METHODS AND MATERIALS: In this study, transcriptome from OSCC patients was downloaded from the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) databases, and differential gene expression analysis was performed using R's 'limma' package. LASSO Cox regression identified key prognostic genes. We stratified patients into low- and high-risk groups and estimated survival rates using Kaplan-Meier. Gene set enrichment analysis (GSEA) and immune infiltration analysis were conducted to understand the potential pathways and tumour microenvironment. A nomogram model was constructed for prognosis prediction.
resultsOur study identified 118 candidate genes from three data sets and narrowed them down to four prognostic genes (IGF2BP2, PLAU, CEP55, CMYA5) using univariate Cox regression and LASSO Cox regression. A risk score model was developed which could predict patient prognosis. The model's prognostic value was independent of age, gender, and stage. A nomogram model incorporating risk score and age was constructed for personalised survival prediction. Tumour mutation burden analysis showed that the mutation rate of TP53 was higher in the high-risk group. Immune landscape analysis uncovered distinct immune cell infiltration patterns and immune checkpoint expression levels between different risk groups, suggesting implications for immunotherapy strategies.
conclusionThe risk score model constructed using drug-sensitivity-related genes IGF2BP2, PLAU, CEP55, and CMYA5 may predict the prognosis of OSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.